Complex Trials, Clear Budgets: Global Clinical Trial Budgeting Strategies
Webinar Date/Time: Wednesday, May 22, 2024 at 11am EDT | 8am PDT | 4pm BST | 5pm CEST
Elevate your clinical trial budgeting skills with IQVIA Technologies’ expert insights. Learn to navigate the complexities of multi-country trials and accelerate your budget finalization.
Register Free: https://www.appliedclinicaltrialsonline.com/act/trial-budgeting-strategies
Event overview
Join IQVIA Technologies for an informative webinar exploring the intricacies of clinical trial budgeting. As trials continue to grow in complexity and scale, understanding budget building best practices is crucial.
This presentation considers the complexities of conducting trials across multiple countries and sites, and the growing demand for accelerating budget finalization to bring much needed medications and therapies into the market quicker. Don’t miss your chance to learn about strategies on effective budget building methods and how technology can provide a comprehensive solution for managing investigator grant costs.
Three key take-aways
- Discuss the complexities of managing clinical trial budget development and finalization and their impact on study start-up.
- Gain insights into effective methods for clinical trial budgeting, highlighting the importance of real-time projections, technology, and consistent processes across studies.
- Explore the role of technology in managing investigator grant costs.
Speakers:
Brenda Mull
Associate Director, Business Operations, Cost Benchmarking
IQVIA Technologies
Brenda Mull leads the Cost Benchmarking operations team and is the business owner of the GrantPlan suite of products, which offers best-in-class budget development solutions for sponsors, CROs and investigators. She has more than a decade of experience in contracting and budget negotiations for clinical trial study start-up, with deep knowledge and a strong focus on budget development. With more than 30 years in the healthcare industry, she is passionate about bringing technology to the clinical trial space to assist with life-changing solutions.
Jyothsna Gade
Associate Director, Product Management, Cost Benchmarking
IQVIA Technologies
Jyothsna is a seasoned professional with over 20 years of experience leading diverse product teams. She is dedicated to providing cutting-edge solutions, consistently emphasizing innovation to ensure that technology aligns seamlessly with the evolving requirements of the clinical trial domain. Jyothsna leads the cost benchmarking product team at IQVIA, with a primary focus on GrantPlan, a trial-budgeting solution to help sponsors, CROs and sites.
Register Free: https://www.appliedclinicaltrialsonline.com/act/trial-budgeting-strategies
Newsletter
Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
FDA Issues Complete Response Letter to Replimune for RP1 Combination Therapy in Advanced Melanoma
July 22nd 2025The FDA’s complete response letter cited concerns that the Phase I/II IGNYTE (NCT03767348) trial in advanced melanoma was not an adequate, well-controlled study and that its heterogeneous patient population limited interpretability, preventing approval in its current form.
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
New FDA Initiative Reveals Common Reasons for Drug Application Rejection
July 11th 2025By publishing more than 200 complete response letters, the FDA is offering new visibility into the issues that most often delay drug approvals, including safety concerns, trial design flaws, and manufacturing gaps.
